Johnson & Johnson knew of TrapEase filter complications as early as 2011
Medical device maker Johnson & Johnson knew about complications associated with the TrapEase inferior vena cava (IVC) filter as early as 2011. A Japanese study conducted at the time found that the TrapEase IVC filters had an abnormally high rate of fracture in patients who received them to prevent blood clots when anti-clotting medications prove ineffective.
In the study, 20 patients received the TrapEase IVC filter in their inferior vena cava, the main vein responsible for bringing blood back to the heart. By the 50 month period of the trial, half of them experienced a device fracture, leading pieces of the device to travel through the bloodstream to other parts of the body.
IVC filter fracturing can lead to many serious complications. TrapEase side effects include blood clots, thromboembolism, failure to deploy, device migration and fracture. Patients have begun filing IVC filter lawsuits after suffering complications from the devices.